<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03940677</url>
  </required_header>
  <id_info>
    <org_study_id>2018-A02413-52</org_study_id>
    <nct_id>NCT03940677</nct_id>
  </id_info>
  <brief_title>Innovative Biomarkers in de Novo Parkinson's Disease</brief_title>
  <acronym>INNOBIOPARK</acronym>
  <official_title>Innovative Biomarkers in de Novo Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Grenoble Institut des Neurosciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at identifying potential new and innovative biomarkers in de novo Parkinson's
      disease patients. New finding will help phenotyping patients since the diagnosis of the
      disease and potentially also in the preclinical phase.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will use 4 different approaches in parallel:

        1. detailed clinical evaluation using the current available validated clinical scales and
           the Dopamine transporter (DAT) SPECT imaging;

        2. anatomical and perfusional brain evaluation using functional MRI;

        3. cortical brain mapping and transcranial magnetic stimulation assessment using a
           robotized approach;

        4. emotional responses study using a novel paradigm. These 4 modalities will be assessed at
           baseline, 1 year and 2 years follow-up.

      The investigators will integrate these 4 analysis using a mathematical paradigm in order to
      define specific phenotype of disease and disease progression.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 29, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 28, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare cortical excitability differences between subjects</measure>
    <time_frame>In a seven months period after inclusion</time_frame>
    <description>The EEG data after transcranial magnetic stimulation testing will be compared between parkinsonian patients and controls</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To compare brain structural differences between subjects</measure>
    <time_frame>In a seven months period after inclusion</time_frame>
    <description>All subjects will have a 3 Tesla brain MRI to collect data concerning anatomy. All data will be compared between patients and controls. Brain MRI study will consist in having the following sequences: T1 and T2, Fast Gray Matter Acquisition T1 Inversion Recovery (FGATIR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To compare brain perfusional differences between subjects</measure>
    <time_frame>In a seven months period after inclusion</time_frame>
    <description>All subjects will have a 3 Tesla brain MRI to collect data concerning perfusion. All data will be compared between patients and controls. Brain MRI study will consist in having the following sequences: Pseudo-Continuous Arterial Spin Labeling (PCASL), T2 with gadolinium, FLAIR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To compare brain connectivity differences between subjects</measure>
    <time_frame>In a seven months period after inclusion</time_frame>
    <description>All subjects will have a 3 Tesla brain MRI to collect data concerning functional connectivity at rest. All data will be compared between patients and controls. Brain MRI study will consist in having the following sequences: Echo planar imaging (EPI) for the blood oxygen level-dependent effect</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To compare emotional, attentional and behavior differences between subject</measure>
    <time_frame>In a seven months period after inclusion</time_frame>
    <description>Subjects will be asked to comment on different pictures (if the picture induces pleasure, sorrow or nothing; what would the subjects do). Attentional parameters will be recorded using the Eye tracker.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To compare emotional, attentional and behavior differences between subject with functional MRI</measure>
    <time_frame>In a seven months period after inclusion</time_frame>
    <description>During a functional MRI study, subjects will be asked to comment on different pictures (if the picture induces pleasure, sorrow or nothing; what would the subjects do). Attentional parameters will be recorded using the Eye tracker.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Parkinson's Disease</condition>
  <condition>Healthy Controls Group - Age and Sex-matched</condition>
  <arm_group>
    <arm_group_label>Parkinson's disease patient</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Brain functional MRI, robotic TMS + EEG, neuropsychological evaluation, neurological examination for motor and non motor symptoms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Brain functional MRI, robotic TMS + EEG, neuropsychological evaluation, neurological examination</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Brain MRI</intervention_name>
    <description>3 Tesla brain MRI for structural and perfusion evaluation, resting state analysis and functional MRI</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Parkinson's disease patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TMS-EEG</intervention_name>
    <description>Transcranial magnetic stimulation (TMS) coupled with electroencephalogram (EEG) study</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Parkinson's disease patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral and cognitive battery</intervention_name>
    <description>Emotional, attentional and behavioral assessment using predefine scales and measures</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Parkinson's disease patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical evaluation and clinical scales</intervention_name>
    <description>Neurological evaluation, ophthalmologic assessement, Montreal cognitive assessment (MoCA), movement disorder society (MDS)- UPDRS</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Parkinson's disease patient</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Parkinson's disease

          -  Asymmetric bradykinesia and/or resting tremor and rigidity since less than 2.5 years ;

          -  Hoehn &amp; Yahr ≤ 2/5 ;

          -  Montreal cognitive assessment ≥ 26/30 ;

        Exclusion Criteria:

          -  Treatment for Parkinson's disease (except selegiline and rasagiline)

          -  Severe visual/retinal pathology revealed during ophthalmological assessment

          -  Hyper-sensibility to gadolinium

          -  Renal failure

          -  Specific MRI contraindication

          -  Specific TMS contraindication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Moro, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Grenoble Alpes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre Pelissier, Master</last_name>
    <phone>+ 33 4 76 76 94 59</phone>
    <email>ppelissier@chu-grenoble.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Grenoble Alpes</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Pelissier, Master</last_name>
      <phone>+ 33 4 76 76 94 59</phone>
      <email>ppelissier@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Valerie Fraix, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sara Meoni, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Castrioto, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie Fournier, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 4, 2019</study_first_submitted>
  <study_first_submitted_qc>May 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2019</study_first_posted>
  <last_update_submitted>May 3, 2019</last_update_submitted>
  <last_update_submitted_qc>May 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Biomarkers</keyword>
  <keyword>Magnetic resonance imaging (MRI)</keyword>
  <keyword>Neuropsychology</keyword>
  <keyword>Transcranial magnetic stimulation (TMS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

